FDA expands Moringa salmonella outbreak warning as recall grows to 119 cases across 36 states

The FDA expanded its warning on a Salmonella outbreak linked to Rosabella brand moringa powder capsules, reporting 119 cases across 36 states as of April 2026, officials said. The investigation was reopened after new information revealed an additional 22 illnesses involving an extensively drug-resistant Salmonella strain, prompting continued recalls and consumer advisories.

The outbreak involves an extensively drug-resistant strain of Salmonella, which has complicated treatment efforts, federal officials said. The outbreak was initially linked to Rosabella brand moringa powder capsules, produced by Ambrosia Brands, LLC, following a recall issued on February 13, 2026.

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have reported 119 illnesses across 36 states, including 32 hospitalizations, with no deaths confirmed as of April 2026.

The investigation had been closed in March 2026 after the initial recall, but new information prompted the FDA and CDC to reopen the case. According to FDA records and a Food Safety News report, 22 additional illnesses from four states were identified during the reopened investigation, expanding the scope of the outbreak. The FDA and CDC continue to trace and sample products while issuing public advisories to consumers and retailers.

The recalled Rosabella moringa powder capsules were found to be contaminated with Salmonella and were distributed nationwide and internationally, the FDA said. Consumers and retailers have been urged to check lot codes and not to consume, sell, or distribute any recalled lots. The FDA advises anyone with the product to discard or return it. The agency also recommends cleaning and sanitizing surfaces and containers that may have come into contact with the recalled capsules to prevent cross-contamination.

The CDC has warned that Salmonella infections can cause serious illness, especially in young children, older adults, and people with weakened immune systems. Symptoms include diarrhea accompanied by fever, bloody diarrhea, vomiting that prevents drinking fluids, and signs of dehydration. The CDC advises anyone experiencing these symptoms to seek medical attention promptly. The FDA has also encouraged healthcare providers and consumers to report any adverse events related to the recalled products through its MedWatch program.

The outbreak is part of a broader pattern of Salmonella cases linked to moringa leaf powder products in 2026. An earlier FDA investigation documented 11 cases across seven states in October 2025, with three hospitalizations and no deaths, but the contamination source was not identified at that time. Another 2026 outbreak involved 18 illnesses across 14 states, indicating multiple moringa-related Salmonella events in the same year, according to public health reports.

The FDA and CDC have worked jointly with state and local health departments to investigate the outbreak, using epidemiologic and laboratory evidence to link cases to the contaminated moringa capsules. Traceback efforts identified organic moringa leaf powder as the vehicle for the earlier outbreak, though the precise contamination source remains unknown. Ambrosia Brands, LLC has provided a contact number, 914-768-1357, for consumers seeking information during business hours.

Federal officials continue to monitor the situation closely as the investigation proceeds. They have emphasized the importance of ongoing public health surveillance and consumer vigilance to prevent further illnesses linked to contaminated dietary supplements containing moringa leaf powder.